John S. McBride - 10 Jan 2026 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Role
Director
Signature
/s/ Paul Little, as attorney-in-fact for John McBride
Issuer symbol
ELDN
Transactions as of
10 Jan 2026
Net transactions value
$0
Form type
4
Filing time
16 Jan 2026, 17:00:10 UTC
Previous filing
13 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McBride John S. Director C/O ELEDON PHARMACEUTICALS, INC., 19800 MACARTHUR BLVD STE. 250, IRVINE /s/ Paul Little, as attorney-in-fact for John McBride 16 Jan 2026 0001618251

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELDN Common Stock Options Exercise $0 +3,430 $0.000000 3,430 10 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELDN Restricted Stock Units Options Exercise $0 -3,430 -100% $0.000000 0 10 Jan 2026 Common Stock 3,430 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.